• 11-AUG-2014

  • SOURCE: Novo Nordisk A/S

FOR UK MEDICAL MEDIA ONLY <br><br> Phase 3a data demonstrates efficacy and tolerability of IDegLira (insulin degludec/liraglutide; Xultophy®) in adults with type 2 diabetes

Novo Nordisk Logo
Today, Diabetes Care publishes phase 3a findings demonstrating a significantly greater glucose-lowering effect with IDegLira (insulin degludec/liraglutide; Xultophy®) compared to insulin degludec. People on IDegLira also experienced a low rate of hypoglycaemia, comparable to insulin degludec, and achieved a reduction in body weight when compared to treatment with basal insulin alone. The data are from the DUal Action of Liraglutide and insulin degludec in type 2 diabetes (DUAL™ II) trial investigating IDegLira, the first once-daily basal insulin (insulin degludec, Tresiba®▼) and GLP-1 receptor agonist (liraglutide, Victoza®) in one pen.

IDegLira demonstrated a mean HbA1c reduction of 1.9% from baseline, versus 0.9% with insulin degludec. Sixty percent of people treated with IDegLira achieved the HbA1c goal of less than 53mmol/mol (˂7.0%) compared to 23% treated with insulin degludec (p<0.0001). People treated with IDegLira had a significant mean weight loss of 2.7 kg from baseline compared to no change with insulin degludec (p<0.0001). Forty percent of the people treated with IDegLira, achieved the HbA1c goal with no confirmed hypoglycaemic episodes and with no weight gain, compared to 8.5% of people treated with insulin degludec (p<0.0001).